Companies › Evopoint Biosciences
3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XNW28012 for Injection | – | Phase 3 | Pancreatic Cancer; Advanced Solid Tumors | Dec 2026 |
| XNW5004 tablets EZH2 inhibitor | EZH2 | Phase 3 | Relapsed/Refractory Peripheral T Cell Lymphoma; Follicular Lymphoma, Grade 1; Metastatic Castrate-Resistant Prostate Cancer | Jul 2027 |
| XNW29016 PARG inhibitor | PARG | Phase 1 | Tumor, Solid | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06799637 | XNW28012 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06987500 | XNW29016 | Phase 1 | Tumor, Solid | Oncology | Feb 2027 |
| NCT07823049 | XNW28012 for Injection | Phase 3 | Pancreatic Cancer | Oncology | May 2027 |
| NCT06702995 | XNW5004 tablets | Phase 1 | Metastatic Castrate-Resistant Prostate Cancer | Oncology | Jul 2027 |
| NCT07545603 | XNW5004 tablets | Phase 2 | Follicular Lymphoma, Grade 1 | Oncology | Dec 2027 |
| NCT06776952 | XNW5004 tablets | Phase 3 | Relapsed/Refractory Peripheral T Cell Lymphoma | Oncology | Jan 2028 |
FoRx Therapeutics 858 Therapeutics IDEAYA Biosciences Novartis Epizyme Daiichi Sankyo Hanmi Pharmaceutical Company
Guangzhou Gloria Biosciences Nuvation Bio Allist Pharmaceuticals Shanghai Kechow Pharma Dizal Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.